Article
18 Jun 2025
Third Circuit Holds That Granting Discovery Under Section 1782 Is Not A "Final" Judgment
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
14 May 2025
EMA Issues Positive CHMP Opinions For Biocon's Denosumab Biosimilars
Article
08 Apr 2025
Commercialization Of Ustekinumab And Golimumab Biosimilars
Article
30 Dec 2024
Bio-Thera Solutions Expands Partnership With SteinCares To Market Two Biosimilars In LATAM
Article
18 Nov 2024
Celltrion Launches STEQEYMA (Ustekinumab) In Germany And The Netherlands
Article
09 Sep 2024
PTAB Institutes Sarepta's IPR
Article
02 Jul 2024
Biogen's TOFIDENCE (Tocilizumab) Approved In The EU
Article
05 Jun 2024
USPTO Proposed Rulemaking Regarding Terminal Disclaimers
Article
24 Apr 2024
Genentech And Dr. Reddy's Settle BPCIA Rituximab Litigation
Article
21 Mar 2024
Celltrion Submits BLA For Omalizumab Biosimilar
Article
16 Jan 2024
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.
Article
30 Sep 2023
FDA Releases Draft Labeling Guidance For Biosimilar Products
Article
29 Sep 2023
Is It Biosimilar Or Interchangeable? It Won't Be Easy To Tell Under FDA's Latest Draft Labeling Guidance
Article
21 Aug 2023
Sarepta And Catalent File Answers In REGENXBIO v. Sarepta Litigation
Article
18 Jul 2023
Post-Trial Briefing In Regeneron V. Mylan Aflibercept BPCIA Case
Article
10 May 2023
Samsung Files IPR Petition On Regeneron's Aflibercept Patent
Article
04 Apr 2023
White House Announces "Bold Goals" For Biotech
Article
03 Mar 2023
Court Denies Amgen's Motion To Dismiss And Motion To Stay Regeneron's Antitrust Case
Article
25 Jan 2023
Chinese Market Biosimilar Update
Article
15 Dec 2022
BPCIA Aflibercept Litigation: Mylan Seeks Leave To Add A Declaratory Judgment Counterclaim Of No Lost Profits Or Injunctive Relief